Beclometasone–formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial

Papi, Alberto; Corradi, Massimo; Pigeon-Francisco, C.; Baronio, Roberta; Siergiejko, Zenon; Petruzzelli, Stefano; Fabbri, Leonardo M.; Rabe, Klaus F.

doi:10.1016/s2213-2600(13)70012-2

Cited by 144 publications

(143 citation statements)

References 28 publications

Supporting

Mentioning

126

Contrasting

Unclassified

Order By: Relevance

“…Adding LABA to the same dose of ICS provides additional improvements in symptoms and lung function with a reduced risk of exacerbations 166 (Evidence A). In at-risk patients, the ICS/formoterol maintenance and reliever regimen significantly reduces exacerbations and provides similar levels of asthma control at relatively low doses of ICS, compared with a fixed dose of ICS/LABA as maintenance treatment or a higher dose of ICS, both with asneeded SABA [167][168][169][170][171] (Evidence A).…”

Section: Preferred Option (Adults/adolescents): Combination Low Dose mentioning

confidence: 99%

“…The combination of rapid-onset LABA (formoterol) and low dose ICS (budesonide or beclometasone) in a single inhaler as both the controller and the reliever medication is effective in improving asthma control, 140 and in at-risk patients, reduces exacerbations requiring OCS, and hospitalizations [167][168][169][170] (Evidence A). The combination ICS/formoterol inhaler may be taken up to a maximum total formoterol dose of 72 mcg in a day (Evidence A).…”

Section: Combination Low Dose Ics (Budesonide or Beclometasone) With mentioning

confidence: 99%

See 1 more Smart Citation

Mortality in Asthma-Chronic Obstructive Pulmonary Disease Overlap in the United States

Kumbhare

Strange

2018

Southern Medical Journal

View full text Add to dashboard Cite

Section: Preferred Option (Adults/adolescents): Combination Low Dose mentioning

confidence: 99%

Section: Combination Low Dose Ics (Budesonide or Beclometasone) With mentioning

confidence: 99%

Mortality in Asthma-Chronic Obstructive Pulmonary Disease Overlap in the United States

Kumbhare

Strange

2018

Southern Medical Journal

View full text Add to dashboard Cite

“…6 Universidad "Juárez" Autónoma de Tabasco. Villahermosa, Tabasco 39 Colegio Nacional de Enfermeras. Ciudad de México 40 Secretaría de Salud, Instituto Nacional de Pediatría, Departamento de Neumología y Cirugía de Tórax.…”

Section: Pasos En La Elaboración De Guima 2017unclassified

“…Camargo-Angeles, 35 Rogelio García-Torrentera, 20 Saraí Toral-Freyre, 20 Gabriel Montes-Narváez, 25 Héctor Solorio-Gómez, 36 Juan Rosas-Peña, 37 Sergio Jesús Romero-Tapia, 38 Adela Reyes-Herrera, 39 Francisco Cuevas-Schacht, 40 Joaquín Esquer-Flores, 41 José Antonio Sacre-Hazouri, …”

unclassified

Guía Mexicana del Asma: GUIMA 2017

Larenas-Linnemann¹,

Salas-Hernández²,

Vázquez-García³

et al. 2017

RAM

View full text Add to dashboard Cite

Este artículo debe citarse como: Larenas-Linnemann D, Salas-Hernández J, Vázquez-García JC, Ortiz-Aldana I, Fernández-Vega M, Del Río-Navarro BE, et al. Guía Mexicana del Asma 2017. Rev Alerg Mex. 2017;64 Supl 1:s11-s128. AbstractBackground: The need for a national guideline, with a broad basis among specialists and primary care physicians was felt in Mexico, to try unifying asthma management. As several high-quality asthma guidelines exist worldwide, it was decided to select the best three for transculturation. Methods: Following the internationally recommended methodology for guideline transculturation, ADAPTE, a literature search for asthma guidelines, published 1-1-2007 through 31-12-2015 was conducted. AGREE-II evaluations yielded 3/40 most suitable for transculturation. Their compound evidence was fused with local reality, patient preference, cost and safety considerations to draft the guideline document. Subsequently, this was adjusted by physicians from 12 national medical societies in several rounds of a Delphi process and 3 face-to-face meetings to reach the final version. Results: Evidence was fused from British Thoracic Society Asthma Guideline 2014, Global Initiative on Asthma 2015, and Guía Española del Manejo del Asma 2015 (2016 updates included). After 3 Delphi-rounds we developed an evidence-based document taking into account patient characteristics, including age, treatment costs and safety and best locally available medication. Conclusion: In cooperation pulmonologists, allergists, ENT physicians, paediatricians and GPs were able to develop an evidence-based document for the prevention, diagnosis and treatment of asthma and its exacerbations in Mexico.Keywords: Clinical practice guideline; Asthma; Asthmatic exacerbation; Bronchodilator; Inhaled corticosteroid; Spirometry; Immunotherapy. IntroducciónLa presentación de este documento muestra la importancia del asma en México por su alta prevalencia, pero también por su subdiagnóstico y tratamiento deficiente, que propician un mal control de los pacientes con asma, crisis más frecuentes y sintomatología activa. En consecuencia, el asma tiene un impacto socioeconómico considerable para el paciente y la sociedad en su conjunto, al igual que afecta la calidad de vida del paciente y su familia. En México, el paciente con asma puede recibir atención médica en los ámbitos pú-blico o privado, en los diferentes niveles de salud y por múltiples especialidades. Todas estas particularidades de la situación nacional indican la necesidad de un documento guía actualizado, con base amplia en múltiples gremios médicos, tanto de primer nivel de atención como de especialidad.El objetivo de la GUIMA 2017 es facilitar la reducción de la morbimortalidad por asma en México, no solo al mejorar el conocimiento acerca de esta patología, sino también al ayudar a la parte administrativa del Sector Salud a gestionar la selección y adquisición más precisa de los medicamentos necesarios para su tratamiento a nivel de la salud pública. Para tal fin se ofrecen lineamientos par...

show abstract

“…Этот подход снижает риск тяже-лых обострений у взрослых и подростков [24][25][26], а также у детей в возрасте 4-11 лет [27]. С использова-нием методологии скрытого электронного мониторин-га ингаляторов было показано, что режим SMART сни-жал количество дней с плохой приверженностью тера-пии ИКС по сравнению со стандартной регулярной терапией с двукратным приемом фиксированной ком-бинации [25].…”

Section: подходы к терапии икс при баunclassified

Early Prescription of Inhalation Corticosteroid in Bronchial Asthma

Айсанов¹,

Калманова²,

Стулова³

2017

Med. sov.

View full text Add to dashboard Cite

П о данным разных авторов, от 50 до 75% боль-ных бронхиальной астмой (БА) страдают лег-кой формой заболевания, однако риск обо-стрения не всегда адекватно оценивается [1]. Долго-срочными целями лечения БА, включая легкое течение заболевания, являются контроль симптомов и минимиза-ция рисков будущих обострений, развития фиксирован-ной бронхиальной обструкции и побочных эффектов проводимой терапии [2]. Тем не менее течение астмы во многих случаях не удается контролировать, несмотря на имеющиеся на сегодняшний день в распоряжении врача эффективные лечебные режимы [1,3]. ПАТОФИЗИОЛОГИЧЕСКИЕ И МОЛЕКУЛЯРНЫЕ МЕХАНИЗМЫ КОМБИНИРОВАННОЙ ТЕРАПИИСимптомы БА связаны не только с бронхоконстрикци-ей, но и с воспалением дыхательных путей (ДП) [4][5][6][7][8], и обе группы препаратов -как бета2-агонисты (Б2А), так и ингаляционные кортикостероиды (ИКС) обладают быстрым противовоспалительным действием.Ингаляционные Б2А помимо расслабляющего дей-ствия на гладкую мускулатуру бронхов обладают и небронходилатационными эффектами, что обусловлива-ет их влияние на обострения астмы. Бета-агонисты спо-

show abstract

Beclometasone–formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial

Cited by 144 publications

References 28 publications

Mortality in Asthma-Chronic Obstructive Pulmonary Disease Overlap in the United States

Mortality in Asthma-Chronic Obstructive Pulmonary Disease Overlap in the United States

Guía Mexicana del Asma: GUIMA 2017

Early Prescription of Inhalation Corticosteroid in Bronchial Asthma

Contact Info

Product

Resources

About